Centre Hospitalier Universitaire De Nimes
- Address
- lock Available on a paid plan
Cardiovascular and Metabolic Research
The clinical trial portfolio at Centre Hospitalier Universitaire De Nimes includes a strong focus on cardiovascular diseases and metabolic disorders, with studies in atherosclerotic cardiovascular disease, heart failure, hypertension, and diabetes-related complications. These trials are designed to test new treatments and prevention strategies, while also improving long-term risk reduction and patient outcomes.
- Cardiovascular disease, including prevention of major events and recovery after acute episodes
- Heart failure, hypertension, and vascular risk management
- Metabolic conditions such as diabetic kidney disease and lipid-related risk
Research in this area also explores ways to better protect high-risk patients through improved treatment effectiveness and follow-up care.
Oncology and Hematology
A major part of the research activity at this site covers cancer and blood disorders, especially breast cancer, lung cancer, urothelial cancer, prostate cancer, and lymphomas. The studies aim to evaluate new anticancer therapies, improve disease control, and support better survival outcomes across both solid tumors and hematologic malignancies.
- Breast cancer, including triple-negative and hormone receptor-positive disease
- Leukemia, myelodysplastic syndromes, and myelofibrosis
- Lymphomas, multiple myeloma, and other advanced blood cancers
- Urothelial, prostate, lung, and head and neck cancers
Much of this work focuses on testing new treatment combinations and refining care for patients with advanced or hard-to-treat disease.
Neurology and Movement Disorders
The site conducts extensive research in neurological diseases, particularly multiple sclerosis, Parkinson’s disease, migraine, and other movement or cognitive disorders. These trials are aimed at slowing progression, reducing symptoms, and improving everyday functioning for people living with chronic neurological conditions.
- Multiple sclerosis, including relapsing and progressive forms
- Parkinson’s disease and related motor fluctuations
- Migraine, tremor, and other movement disorders
- Psychogenic non-epileptic seizures and cognitive impairment-related studies
This area reflects a broad effort to test therapies that may improve symptoms, preserve mobility, and support long-term neurological health.
Gastroenterology, Inflammation, and Autoimmune Disease
Clinical research at Centre Hospitalier Universitaire De Nimes also includes a strong presence in digestive system diseases and immune-mediated conditions. Key studies involve Crohn’s disease, ulcerative colitis, IgA nephropathy, and several autoimmune disorders, with the goal of improving disease control and reducing complications.
- Crohn’s disease and ulcerative colitis
- IgA nephropathy and other immune-related kidney diseases
- Rheumatoid arthritis, juvenile idiopathic arthritis, and vasculitis
- Inflammatory bowel disease recurrence prevention and symptom management
These trials commonly focus on better symptom control, preventing relapse, and evaluating more effective treatment approaches for chronic inflammatory illness.
Kidney, Urology, and Renal-Associated Research
Another important research stream involves kidney disease and urologic cancers, including chronic kidney disease, end-stage renal disease, glomerular diseases, and bladder cancer. The studies are intended to improve kidney function preservation, refine cancer care, and support better management of urinary tract conditions.
- Chronic kidney disease, acute kidney injury, and dialysis-related care
- IgA nephropathy, membranous nephropathy, and focal segmental glomerulosclerosis
- Bladder, urothelial, and renal cell cancers
- Urinary tract infections and related complications
Research in this field is centered on improving treatment effectiveness while limiting progression and recurrence.
Infectious Diseases, Critical Care, and Perioperative Research
The site participates in trials across infectious diseases, critical care, and perioperative medicine. Studies include COVID-19, septic shock, pneumonia, and serious bacterial infections, alongside research on anesthesia and surgical care. The overall aim is to improve survival, reduce complications, and optimize care for hospitalized patients.
- Sepsis, septic shock, and severe hospital infections
- Pneumonia and other respiratory infections
- Perioperative anesthesia, pain control, and surgical support
- Vaccine and infection-prevention studies
This area combines treatment evaluation with practical efforts to improve care in acute and high-risk clinical settings.
Psychiatry, Addiction, and Quality-of-Life Research
Research also extends into mental health and addiction medicine, with studies in major depressive disorder, schizophrenia, alcohol use disorder, and related behavioral conditions. These trials are generally aimed at testing new therapies, improving symptom relief, and supporting better daily functioning.
- Depression and mood disorders
- Schizophrenia and cognitive impairment
- Alcohol dependence and substance use disorders
- Brain function and symptom-focused supportive research
At this hospital site, these studies broaden the research profile beyond physical disease and into patient-centered mental health care.
Pediatric, Neonatal, and Reproductive Health
The research portfolio includes selected studies in neonatal, pediatric, and reproductive health areas. Conditions studied include preterm infant complications, respiratory distress in newborns, and pregnancy-related risks, with a focus on improving early-life care and maternal outcomes.
- Preterm infants and feeding or respiratory complications
- Pregnancy complications and high-risk obstetric care
- Pediatric neurological and surgical conditions
These trials are designed to support safer care for vulnerable patients at the start of life and during pregnancy.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 28 therapeutic areas and 15 of 529 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 469 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 89 by active trials.
lock +88 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +50 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier Universitaire De Nimes
lock Showing 1 of 302 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| "CUPCAKE": Early detection of triple negative breast cancer relapse: a clinical utility trial | Institut Curie | Phase II | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 529 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sodium Chloride | 23 | Unknown | 2017-05-31 | 2026-06-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
